SiBone (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 3,310 Shares

SiBone (NASDAQ:SIBN - Get Free Report) insider Anthony J. Recupero sold 3,310 shares of the business's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $18.27, for a total transaction of $60,473.70. Following the transaction, the insider owned 279,121 shares in the company, valued at $5,099,540.67. This represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

SiBone Price Performance

Shares of NASDAQ SIBN traded down $0.46 during midday trading on Monday, reaching $18.01. The stock had a trading volume of 344,646 shares, compared to its average volume of 395,174. The stock has a 50-day moving average of $17.89 and a 200-day moving average of $16.23. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. The company has a market capitalization of $767.59 million, a price-to-earnings ratio of -28.14 and a beta of 0.93. SiBone has a 12-month low of $11.70 and a 12-month high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. As a group, research analysts anticipate that SiBone will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On SiBone

Several institutional investors have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new stake in SiBone during the 1st quarter valued at about $34,000. Virtus Fund Advisers LLC bought a new stake in SiBone during the 4th quarter valued at about $40,000. GAMMA Investing LLC lifted its holdings in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after buying an additional 3,867 shares in the last quarter. Virtus Advisers LLC purchased a new position in SiBone during the 1st quarter valued at about $58,000. Finally, KLP Kapitalforvaltning AS purchased a new position in SiBone during the 4th quarter valued at about $97,000. Institutional investors own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of SiBone in a report on Tuesday, May 6th. Finally, Truist Financial upped their price objective on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.